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Abstract
Rationale Imperatorin, a naturally occurring furanocoumarin,
inactivates gamma-aminobutyric acid transaminase and in-
hibits acetylcholinesterase activity.
Objectives The purpose of our experiment was to examine the
influence of imperatorin on cognitive impairment and oxidative
stress in the brain induced by scopolamine in male Swiss mice.
Methods In the present studies, we used scopolamine-invoke
memory deficit measured in passive avoidance (PA) paradigm
as an animal model of Alzheimer disease (AD).
Results Our finding revealed that imperatorin administered
acutely at the doses of 5 and 10 mg/kg prior to the injection
of scopolamine (1 mg/kg) improved memory acquisition and
consolidation impaired by scopolamine. Furthermore, repeat-
able (7 days, twice daily) administration of the highest dose of
imperatorin (10 mg/kg) significantly attenuated the effects of
scopolamine on memory acquisition, whereas the doses of 5
and 10 mg/kg of this furanocoumarin were effective when
memory consolidation was measured. Imperatorin, adminis-
tered with scopolamine, increased antioxidant enzymes activi-
ty and decreased concentration of malondiamide, an indicator
of lipid peroxidation level.
Conclusions These results demonstrate that imperatorin may
offer protection against scopolamine-inducedmemory impair-
ments and possesses antioxidant properties, thus after further
preclinical and clinical studies this compound may provide an
interesting approach in pharmacotherapy, as well as prophy-
lactics of AD.




men-7-one] is a naturally occurring furanocoumarin, which
can be found in citrus fruits, umbelliferous vegetables, and
selected herbal medicines, namely in the roots and fruits of
Angelica dahurica and Angelica archangelica (Umbelliferae,
Apiaceae) (Baek et al. 2000). In recent years, much of the
interest in this compound has centered on its pharmacological
activities. Many experimental studies have shown that impera-
torin possess anti-inflammatory and antitumor properties
(Abed et al. 2001; Ban et al. 2003; Garcia-Argaez et al.
2000; Kawaii et al. 2001), and shows anti-HIV influences
(Sancho et al. 2004) and anticonvulsant action (Łuszczki
et al. 2007). Moreover, our previous study revealed that acute
and repeated administration of imperatorin improves different
stages of memory processes (both acquisition and consolida-
tion) in the modified elevated plus maze test (mEPM), as well
as cognitive functions when coadministered with nicotine
used at the non-active dose (Budzynska et al. 2012, 2013).
We also observed that this coumarin, when administered
acutely and repeatedly, exerts anxiolytic effects on mice mea-
sured in the EPM test (Budzynska et al. 2012). The mecha-
nism of action of imperatorin is connected with the inhibition
of voltage-dependent calcium channels and with the blockade
of serotonin (5-HT) receptors (He et al. 2007). Accumulating
experimental evidence indicates that imperatorin inactivates
gamma-aminobutyric acid (GABA)-transaminase and thus
B. Budzynska (*) :M. Kruk-Slomka :A. Michalak :G. Biala
Department of Pharmacology and Pharmacodynamics, Medical
University of Lublin, Lublin, Poland
e-mail: basia.budzynska@umlub.pl
A. Boguszewska-Czubara : I. Musik
Department of Medical Chemistry, Medical University of Lublin,
Lublin, Poland
K. Skalicka-Wozniak
Department of Pharmacognosy with Medicinal Plants Unit, Medical
University of Lublin, Lublin, Poland
Psychopharmacology (2015) 232:931–942
DOI 10.1007/s00213-014-3728-6
increases the GABA level in the brain (Choi et al. 2005). In
the context of the present experiment, it is important to note
that this compound inhibits acetylcholinesterase (AChE) ac-
tivity (Loizzo et al. 2008). It is established that the cholinergic
system is involved in memory function (Blake et al. 2014).
Cholinergic deficiency in Alzheimer’s disease (AD), particu-
larly in the basal forebrain, seems to be an important factor in
producing dementia (Buckingham et al. 2009; Sugaya et al.
1990). Experimental evidence shows that the activity of
AChE is significantly increased in the cerebral cortex, hippo-
campus, and amygdala in patients with AD (Serrano-Pozo
et al. 2011). Various drugs from the group of acetylcholines-
terase inhibitors (AChEI) (e.g., donepezil, galanthamine,
metrifonate, and rivastigmine) can cause cognitive improve-
ment, which depends on their level of inhibition of the cho-
linesterase activity (Loizzo et al. 2008). However, there are
many limitations on AChEI use, e.g., adverse cholinergic side
effects, hepatotoxicity, or poor bioavailability (Rountree et al.
2009). Moreover, it is important to note that oxidative stress is
believed to be a critical factor in AD, and also inflammatory
and immune mechanisms may play a role in the degenerative
process in this disease (Ding et al. 2007). The central nervous
system (CNS) is very susceptible to oxidative stress as the
brain has a high consumption of oxygen, contains large
amounts of free-radical generating iron and substances like
ascorbate, glutamate, and polyunsaturated fatty acids, that
easily undergo redox-reaction leading to radicals’ formation
and exhibits relatively poor antioxidant defense systems (Wal-
ton et al. 2012). Additionally, coumarins, as well as their
derivatives, were found to exert antioxidant and anti-
inflammatory effects (Kostova 2006; Vianna et al. 2012).
Therefore, the main purpose of this study was to investigate
for the first time the influence of imperatorin on scopolamine-
induced memory impairment in the passive avoidance (PA)
paradigm. It is established that scopolamine induces memory
impairment associated with attenuation of cholinergic neuro-
transmission, as well as an increases of processes connected
with oxidative stress in the brain (Fan et al. 2005). The
activities of antioxidant enzymes superoxide dismutase
(SOD), glutathione peroxidase (GPx), and glutathione reduc-
tase (GR), as well as the concentration of malondialdehyde
(MDA), within the brain tissue, were determined to evaluate




The experiments were carried out on naive male Swiss mice
(Farm of Laboratory Animals, Warszawa, Poland) weighing
20–25 g at the beginning of the experiments. The animals
were maintained under standard laboratory conditions (12 h
light/dark cycle, room temperature 21±1 °C) with free access
to tap water and laboratory chow (Bacutil, Motycz, Poland),
and were adapted to the laboratory conditions for at least
1 week. Each experimental group consisted of 8–12 animals.
All experiments were carried out according to the National
Institute of Health Guidelines for the Care and Use of Labo-
ratory Animals and to the European Community Council
Directive for the Care and Use of Laboratory Animals of 24
November 1986 (86/609/EEC), and were approved by the
local ethics committee. The different mice were used for each
drug and time treatment.
Drugs
The following compounds were tested: scopolamine (Sigma-
Aldrich, St. Louis, MO, USA), rivastigmine tartrate (Tocris
Bioscience, UK), and imperatorin (8-isopentenyloxypsoralen
[9-(3-methylbut-2-enyloxy)-7H-furo[3,2-g]chromen-7-one].
Imperatorin was extracted from fruits of Angelica officinalis
(Angelica archangelica, Apiaceae) collected in August 2011
in Medicinal Plant Garden, Department of Pharmacognosy,
Medical University of Lublin, Poland. The air-dried and pow-
dered fruits (10 g) were extracted under reflux with methanol.
The extract was separated with spectrum high-performance
counter-current chromatograph (Dynamic Extractions,
Slough, UK) equipped with semi-preparative coil with
137 ml capacity. System composed of heptane, ethyl acetate,
methanol, and water (1:1:1:1, v/v) was used for separation, the
upper phase was used as a stationary phase. The apparatus was
rotated at 1,600 rpm, the mobile phase was pumped into the
column at a flow rate of 6.0 ml/min, and the effluent from the
coil was monitored at 254 nm. Eight hundred milligrams of
the crude methanol extract was dissolved in 6 ml of two phase
solvent system and injected into the column through the 6 ml
injection valve. Fractions were collected in every minute.
Imperatorin (0.095 g) with the purity of more than 99 % was
detected in fractions 30–40. The identity and purity of impera-
torin were confirmed by RP-HPLC and 1H NMR analyses.
Scopolamine was dissolved in a saline solution (0.9 %
NaCl). Imperatorin was suspended in a 1 % solution of Tween
80 (Sigma, St. Louis, MO, USA) and also dissolved in a saline
solution. Drugs were administered intraperitoneally (i.p.) at
the volume of 10 ml/kg. Fresh drug solutions were prepared
on each day of experimentation. Control groups received
saline injections of the same volume and via the same route
of administration.
Passive avoidance task
According to Venault et al. (1986), the step-through passive
avoidance task may be recognized as a measure of long-term
memory. The apparatus consisted of a two-compartment
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acrylic box with the lighted compartment (10×13×15 cm)
and the darkened compartment (25×20×15 cm). The light
chamber was illuminated by a fluorescent light bulb (8W) and
was connected to the dark chamber which was equipped with
the electric grid floor. Entrance of animals to the dark box was
punished by an electric foot shock (0.2 mA for 2 s).
On the first day of training (pretest), mice were placed
individually into the light compartment and allowed to ex-
plore the light box. After 30 s, the guillotine door was raised to
allow the mice to enter the dark compartment. When the mice
entered the dark compartment, the guillotine door was closed
and an electric foot shock (0.2 mA) of 2 s duration was
delivered immediately to the animal via the grid floor. The
latency time for entering the dark compartment was recorded
(TL1). If the mouse failed to enter the dark box within 300 s, it
was placed into this dark box, the door was closed, and the
electric foot shock was delivered to the animal. In this case,
TL1 value was recorded as 300 s.
In the subsequent trial (retention), 24 h later, the same mice
were again placed individually in the light compartment of the
PA apparatus. After a 30-s adaptation period in the light (safe)
chamber, the door between the compartments was raised and
the time taken to reenter the dark compartment was recorded
(TL2). No foot shock was applied in this trial. If the animal did
not enter the dark compartment within 300 s, the test was
stopped and TL2 was recorded as 300 s (Allami et al. 2011;
Javadi-Paydar et al. 2012). The experimental procedure in-
volved the examination of both memory acquisition (forma-
tion of memory traces, the animals received substances prior
to the pretest) and memory consolidation (animals received
injections of the substance after the pretest).
Locomotor activity
Locomotor activity of mice was measured with photoresistor
actimeters (circular cages, diameter 25 cm, two light beams).
The animals were placed individually in the actimeter for
60 min. The number of crossings the light beams by the mice
was recorded as the locomotor activity.
Treatment
The doses of imperatorin, rivastigmine, and scopolamine were
chosen based on literature data (Deiana et al. 2009; Gupta
et al. 2012; Łuszczki et al. 2007) and our recently published
article (Budzynska et al. 2012, 2013; Kruk et al. 2011).
Memory-related behavior
During the acute treatment, the animals were allocated to the
following drug groups: saline, rivastigmine (0.5 mg/kg, i.p.),
scopolamine (1 mg/kg, i.p.), imperatorin (1, 5, 10 mg/kg, i.p.),
or imperatorin coadministered with scopolamine. To measure
the memory acquisition processes, scopolamine was adminis-
tered 20 min before the pretest, whereas imperatorin and
rivastigmine were administered 30 min before the pretest. To
measure the memory consolidation processes, rivastigmine or
scopolamine (1 mg/kg) was administered immediately after
the pretest, whereas imperatorin was administered 15 min
after pretest or after scopolamine injection. On the second
day, the mice were retested.
In the second set of the experiments, animals were random-
ly allocated to receive 6 days of i.p. injections of imperatorin
(1, 5, and 10 mg/kg, i.p.) or saline, twice daily (8:00 a.m. and
8:00 p.m.). On the seventh day, these animals were subjected
to saline, scopolamine (1 mg/kg, i.p.), imperatorin (1, 5, and
10 mg/kg, i.p.), or imperatorin coadministered with scopol-
amine. To measure the memory acquisition processes, scopol-
amine was administered 20 min before the pretest and impera-
torin 30 min before the pretest. To measure the memory
consolidation processes, scopolamine (1 mg/kg) was admin-
istered immediately after the pretest, whereas imperatorin was
administered 15 min after the pretest or after scopolamine
injection. On the eighth day, the mice were retested.
Locomotor activity
The animals were allocated to the following drug groups:
saline, scopolamine (1 mg/kg, i.p.), and imperatorin (1, 5,
and 10mg/kg, i.p.) administered alone or 10 min before saline
or scopolamine (1 mg/kg) injection. Immediately after the last
injection, animals were placed into the actimeters.
Tissues collection and preparation
Following the PA test conducted after repeatable administra-
tion of imperatorin mice was anesthetized, the decapitated and
the whole brain were carefully withdrawn and rinsed in icy-
cold isotonic saline to remove the blood. The cerebral cortex
and hippocampus were rapidly dissected. Whole brains (n=
10), as well as the cerebral cortex (n=10) and hippocampus
(n=10), were used for the study.
The collected tissues were homogenized in 10 volumes of
20 mM Tris–HCl buffer (pH 7.4) on ice for 20 s and centri-
fuged at 12,000 g for 30 min at 4 °C. The supernatant was
collected and used for further study. Activities of the antiox-
idant enzymes (SOD, GPx, and GR) and MDA level were
determined from these supernatants spectrophotometrically
with the use of HITACHI 2800 apparatus.
Biochemical estimations
Determination of protein content
The protein content was determined by the Bradford method
(Bradford 1976) using BSA as the standard.
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Determination of SOD activity
The activity of SOD was measured with the use of ready-to-
use diagnostic kits RANSOD by Randox. The method em-
ploys xantine and xantine oxidase (XOD) to generate super-
oxide radicals, which react with iodonitrotetrazolium chloride
to form red formazan dye. The superoxide dismutase activity
is then measured by the degree of inhibition of the reaction.
The increase in absorbance at 505 nm is read.
Determination of GPx activity
The activity of GPx was measured with the use of ready-to-
use diagnostic kits RANSEL by Randox. This method is
based on that of Paglia and Valentine (Paglia and Valentine
1967). GPx catalyzed the oxidation of glutathione (GSH) by
cumene hydroperoxide. In the presence of glutathione reduc-
tase (GR) and NADPH, the oxidized glutatione (GSSG) is
immediately converted to the reduced form with a concomi-
tant oxidation of NADPH to NADP+. The decrease in absor-
bance at 340 nm is measured.
Determination of GR activity
The activity of GR was measured with the use of ready-to-use
diagnostic kits GLUT RED by Randox. The principle of the
method (Goldberg and Spooner 1983) is based on the reaction
of oxidized glutathione (GSSG) reduction in the presence of
NADPH, which is oxidized to NADP+, catalyzed by
glutatione reductase. The decrease in absorbance is measured
at 340 nm.
Estimation of lipid peroxidation products
MDAwas measured by the thiobarbituric acid (TBA) reaction
(Ledwozyw et al. 1986). Briefly, 0.5 ml of tissue homogenate
supernatant was mixed with 2.5 ml 1.22M TCA in 0.6 MHCl
and allowed to stand for 15 min. Then 1.5 ml of 0.9 % TBA
was added, and the mixture was incubated for 30 min in a
boiling water bath. After cooling, 4 ml of n-butanol was added
and the mixture was shaken variously. The samples were
centrifuged at 1,500 g for 10 min, and then the absorbance
of organic phase was measured at 532 nm with respect to
blank (n-butanol alone). The concentration of MDAwas read
from the standard curve obtained by using malonaldehyde bis-
dimethylacetal.
Statistical analysis
The data were expressed as the means±standard error of the
mean (S.E.M). The statistical analyses were performed by the
two-way analysis of variance (ANOVA). Post hoc comparison
of means was carried out with the Tukey’s test for multiple
comparisons, when appropriate. The confidence limit of
p<0.05 was considered a statistically significant.
For the memory-related behaviors, the changes in PA per-
formance were expressed as the difference between retention
and training latencies, and were taken as an index of latency
(IL). IL was calculated for each animal and reports as the ratio:
IL ¼ TL2‐TL1=TL1
TL1 the time taken to enter the dark compartment during
the training
TL2 the time taken to reenter the dark compartment during
the retention (Chimakurthy and Talasila 2010).
Results
Single imperatorin and rivastigmine injection effects
on memory-related processes in PA test in mice
One-way ANOVA revealed that, at the acquisition trial, acute
administration of imperatorin (1, 5, and 10 mg/kg) and
rivastigmine (0.5 mg/kg) changed IL values [F(4,39)=6.008;
p=0.0009]. Indeed, the post hoc Tukey’s test showed that
imperatorin at the doses of 5 and 10 mg/kg (p<0.05 and
<0.01, respectively) and rivastigmine at the dose of 0.5 mg/kg
(p<0.001) significantly increased IL as compared with the
saline-treated mice (Table 1). Similarly, at the consolidation
trial, the acute doses of imperatorin (5 and 10 mg/kg) and
Table 1 Effects of acute administration of imperatorin (IMP; 1, 5, and
10 mg/kg) and rivastigmine (RIVA; 0.5 mg/kg, i.p) on the memory
acquisition or consolidation trials using the PA test in mice. Appropriate
groups of mice received saline, imperatorin (1, 5, or 10 mg/kg, i.p.), or
rivastigmine (RIVA; 0.5 mg/kg, i.p) before the pretest (acquisition) or
after the pretest (consolidation). Data represent the means±SEM and are
expressed as latency index (IL); n=8–12; *p<0.05, **p<0.01,
***p<0.001 versus saline-treated group; Tukey’s test
saline RIVA IMP IMP IMP F p value
0.5 mg/kg 1 mg/kg 5 mg/kg 10 mg/kg
ACQUISITION
IL 2.180±0.294 8.200±0.204*** 2.854±0.396 4.847±0.350* 4.999±0.188** F(4,39)=6.008 0.0009
CONSOLIDATION
IL 2.389±0.129 7.201±1.845*** 1.530±0.388 4.352±0.384* 4.701±0.338** F(4,38)=6,024 0.0009
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rivastigmine (0.5 mg/kg) changed IL, as compared with the
saline-treated mice ([F(4,38)=6.024; p=0.0009], one-way
ANOVA). Indeed, the post hoc Tukey’s test revealed a statis-
tically significant effects: p<0.05 for imperatorin (5 and
10 mg/kg) and rivastigmine (0.5 mg/kg) (Table 1), indicating
that both drugs, at the used doses, improved this stage of
memory and learning processes.
Single imperatorin injection effects on memory-related
processes induced by scopolamine in PA test in mice
Figure 1a indicates the effects of injection of scopolamine
(1 mg/kg) and imperatorin (1, 5, and 10 mg/kg, i.p.) alone or
in combination on memory acquisition during the retention
trial in PA task (two-way ANOVA; pretreatment [F(3,45)=
30.61, p<0.0001], treatment [F(1,45)=21.43, p<0.0001]
without interactions effect [F(3,45)=2.65, p=0.060]). In
scopolamine-treated group, there was a significant decrease
in the IL value as compared with the saline-treated mice
(p<0.001), indicating that scopolamine at the used dose im-
paired acquisition of memory and learning. Furthermore, the
post hoc Tukey’s test revealed a statistically significant im-
provement in cognitive processes in the animals administered
with imperatorin (5 and 10 mg/kg) (p<0.001 and <0.01,
respectively) as compared with the saline-treated mice. Addi-
tionally, administration of imperatorin at the doses of 5 and
10 mg/kg prevented the scopolamine-induced decrease of IL
values as comparedwith the scopolamine group (p<0.001 and
<0.01, respectively).
For memory consolidation during the retention trial, two-
way ANOVA revealed a statistically significant effect caused
by the administration of scopolamine and imperatorin (pre-
treatment [F(3,42)=16.89, p<0.0001], treatment [F(1,42)=
9.19, p<0.0042] without interactions effect [F(3,42)=0.29,
p=0.8306]). The post hoc Tukey’s test showed that scopol-
amine significantly impaired memory consolidation (p<0.01),
whereas imperatorin given alone at the doses of 5 and
10 mg/kg improved cognitive processes (p<0.001) as com-
pared with the saline-treated mice. Moreover, the post hoc
Tukey’s test revealed a statistically significant effect in mem-
ory and learning processes in the animals administered with
scopolamine (1 mg/kg) and imperatorin (5 and 10 mg/kg, i.p.)
or in combination (p<0.01 and <0.05, respectively) (Fig. 1b).
Repeated imperatorin injection effects on memory-related
processes induced by scopolamine in PA test in mice
Figure 2a indicates the effects of repeated injections of im-
peratorin on memory acquisition impaired by scopolamine
during the retention trial in PA task (two-way ANOVA; pre-
treatment [F(3,41)=7.10, p=0.0006], treatment [F(1,41)=
45.95, p<0.0001] without interactions effect [F(3,41)=2.62,
p=0.0635]). The post hoc Tukey’s test revealed that
imperatorin given repeatedly at the doses of 5 and 10 mg/kg
significantly increased IL value as compared with the saline-
treated mice, thus indicating that subchronic administration of
imperatorin improved acquisition of the memory and learning
processes during the retention trial (p<0.05). In contrast, in
mice treated subchronically with saline and on seventh day
with scopolamine (1 mg/kg), we observed impairment of













































































































Fig. 1 Effects of acute administration of imperatorin (IMP; 1, 5, or
10 mg/kg) on the memory acquisition trial (a) or consolidation trial (b)
induced by scopolamine (SCP; 1 mg/kg), using the PA test in mice.
Appropriate groups of mice received saline, imperatorin (1, 5, or
10 mg/kg, i.p.), or scopolamine (1 mg/kg, i.p.), coadministered with
saline or scopolamine (1 mg/kg, i.p.) before the pretest (a) or immediately
after the pretest (b). Data represent the means±SEM and are expressed as
the latency index (IL); n=8–12; the means±SEM; ##p<0.01, ###p<0.001
versus saline-treated control group; *p<0.05, **p<0.01; ***p<0.001
versus scopolamine-treated control group; Tukey’s test
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treated mice. Furthermore, the post hoc Tukey’s test revealed a
statistically significant improvement in memory and learning
processes in the animals administered repeatedly with impera-
torin (10 mg/kg) and on the seventh day injected with
imperatorin in combination with scopolamine (p<0.01) ver-
sus the scopolamine-treated mice.
As it is shown in Fig. 2b, at the consolidation trial, two-way
ANOVA indicated that the mice treated for 6 days, twice daily
with imperatorin (1, 5, and 10 mg/kg) and on the seventh day
administered with imperatorin in combination with scopol-
amine (1mg/kg), demonstrated change of IL values (treatment
[F(1,36)=12.55, p<0.0001] without pretreatment effect
[F(3,36)=2.23, p=0.1442] and interactions effect [F(3,36)=
1.26, p=0.3040]).
The post hoc Tukey’s test showed that injection of impera-
torin on seventh day at the doses of 5 and 10 mg/kg improved
cognitive processes (p<0.05) in rodents, as compared with the
saline-treated mice. Additionally, subchronically treatment
with saline and on seventh day with scopolamine decreased
memory consolidation (p<0.01). It was also revealed that
repeated administration of imperatorin at the doses of 5 and
10 mg/kg significantly improved impairment of memory and
learning processes induced by acute injection of scopol-
amine (p<0.01 and <0.05, respectively), as compared
with the subchronic saline and on the seventh day
scopolamine-treated mice (Fig. 2b).
Locomotor activity
The effect of imperatorin and combined administration of
imperatorin and scopolamine on locomotor activity in mice
is shown in Table 2. Two-way ANOVA indicated changes in
locomotor activity after 30 min (treatment [F(1,52)=63.34,
p<0.0001] without pretreatment effect [F(3,52)=0.92, p=
0.4380] and interactions effect [F(3,52)=0.92, p=0.4380]
and after 60 min (treatment [F(1,52)=82.28, p<0.0001] with-
out pretreatment effect [F(3,52)=0.25, p=0.8584] and inter-
actions effect [F(3,52)=0.50, p=0.6831]. The post hoc
Tukey’s test showed that scopolamine significantly increased
locomotor activity measured 30 and 60 min after administra-
tion as compared with the saline-treated mice (p<0.001 and
<0.01, respectively). Moreover, imperatorin given acutely at
the used doses and after appropriate periods of time did not
affect locomotor activity in mice. Combined administration of
imperatorin and scopolamine did not significantly increase the
locomotor activity counted after 30 and 60 min, when com-
pared with scopolamine-treated group.
Oxidative stress indicators
Table 3 presents the effect of subchronic imperatorin (1, 5, or
10 mg/kg, i.p.) administration and single scopolamine
(1 mg/kg, i.p.) injection, separately or in combination, on
SOD activity within (i) the whole brain (two-way ANOVA;
pretreatment [F(1,88)=11.21, p=0.0012] without treatment
effect [F=(3,88)=0.38, p=0.7681] and interactions effect



































































































































Fig. 2 Effect of subchronic administration of imperatorin (IMP; 1, 5, or
10 mg/kg) on the memory acquisition trial (a) or consolidation trial (b)
induced by scopolamine (SCP; 1 mg/kg), using the PA test in mice.
Imperatorin (1, 5, or 10 mg/kg) or saline was administered for 6 days,
twice daily. On the seventh day, appropriate group of mice received
saline, imperatorin (1, 5, or 10 mg/kg, i.p.), or scopolamine (1 mg/kg,
i.p.), coadministered with saline or scopolamine (1 mg/kg, i.p.) before the
pretest (a) or immediately after the pretest (b). Data represent the means±
SEM and are expressed as latency index (IL); n=8–12; the means±SEM;
#p<0.05, ##p<0.01, ###p<0.001 versus saline-treated control group;
*p<0.05, **p<0.01 versus scopolamine-treated control group; Tukey’s
test
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ANOVA; pretreatment [F(1,88)=16.92, p<0.0001] and inter-
actions effect [F(3,88)=5.39, p=0.0018] without treatment
effect [F=(3,88)=2.13, p=0.1018]), and (iii) the hippocampus
([two-way ANOVA; pretreatment [F(1,88) = 10.87,
p<0.0014], interactions [F(3,88)=4.42, p=0.0061] without
treatment effect [F=(3,88)=2.49, p=0.0654]) of mice. No
significant changes in SOD activity were found in the whole
brain of experimental animals, while the post hoc Tukey’s test
showed that scopolamine administration significantly de-
creased SOD activity in examined brain structures: the cortex
(p<0.001) and hippocampus (p<0.001). In the cortex, im-
peratorin administered with scopolamine was found to in-
crease the activity of SOD at the doses of 5 and 10 mg/kg
(p<0.05), and in the hippocampus, this furanocoumarin
injected at the dose of 10 mg/kg increased the level of SOD
reduced by administration of scopolamine.
Changes in GPx activity in (i) the whole brain ([two-way
ANOVA; pretreatment [F(1,88)=29.00, p<0.001] without
treatment effect [F(3,88)=2.57, p=0.0592] and interactions
[F(3,88)=1.80, p=0.1525]), (ii) the cortex ([two-way
ANOVA; pretreatment [F(1,88)=14.52, p<0.0003], treatment
effect [F(3,88)=4.26, p=0.0074], and interactions [F(3,88)=
3.44, p=0.0203]), and (iii) the hippocampus ([two-way
ANOVA; pretreatment [F(1,88)=98.05, p<0.0001] and inter-
actions [F(3,88)=7.03, p=0.0003], treatment effect [F(3,88)=
4.20, p=0.0080]) are presented in Table 4. In scopolamine-
treated group, significant decrease in GPx activity was noticed
in the whole brain, as well as both examined brain structures
like the prefrontal cortex and hippocampus (p<0.001), in
comparison with saline-treated control group. Moreover, the
post hoc Tukey’s test indicated increasing in GPx activity in
the cortex when imperatorin at the doses of 5 and 10 mg/kg
was administered before scopolamine injection (p<0.01 and
<0.05, respectively), as compared with scopolamine-treated
control group. Also, the changes were statistically significant
in case of the highest dose of imperatorin (10 mg/kg) in the
hippocampus (p<0.01).
Two-way ANOVA analysis revealed a statistically signifi-
cant effect of scopolamine administration in GR activity with-
in the prefrontal cortex (pretreatment [F(1,88)=38.13,
Table 2 Effect of scopolamine (SCP; 1 mg/kg, i.p) and imperatorin
(IMP; 1, 5, and 10 mg/kg, i.p) administered separately or in combination
on spontaneous locomotor activity in mice. Mice were injected with
imperatorin 10 min before scopolamine administration and then
immediately placed in actimeters. Locomotor activity (number of inter-
ruptions of light beams) was recorded for the 30 and 60 min. Data are
presented as the means±SEM. n=8–12, **p<0.01, ***p<0.001 versus
saline-treated group; Tukey’s test





















644.10±47.31 846.50±54.66 709.30±89.75 1,557.00±106.10 1,490.00±103.60 1,497.00±73.68
Table 3 Effect of subchronic administration of imperatorin (IMP; 1, 5, or
10 mg/kg, i.p.) and single scopolamine injection (SCP; 1 mg/kg i.p.) on
the seventh day, separately or jointly, on activity of SOD in the whole
brain, cortex and hippocampus of mice. Data are presented as the means±
SEM; n=8–12; ***p<0.001 versus saline-treated control group, #p<0.05
versus scopolamine-treated control group; Tukey’s test
Treatment SOD [U/mg protein]
Brain Cortex Hippocampus
Saline 2.78±0.09 13.86±0.89 12.97±0.73
SCP 2.38±0.14 9.68±0.75*** 9.38±0.46***
IMP 1 mg/kg 2.96±0.15 13.65±0.29 11.06±0.53
IMP 1 mg/kg+SCP 2.43±0.16 12.38±0.65# 9.76±0.59
IMP 5 mg/kg 2.79±0.16 13.41±0.60 11.49±0.61
IMP 5 mg/kg+SCP 2.49±0.19 12.88±0.46# 11.00±0.22
IMP 10 mg/kg 2.89±0.17 13.87±0.61 11.97±0.83
IMP 10 mg/kg+SCP 2.62±0.17 13.29±0.33# 12.10±0.88#
Table 4 Effect of repeated administration of imperatorin (IMP; 1, 5, or
10 mg/kg, i.p.) and single scopolamine injection (SCP; 1 mg/kg, i.p.) on
the seventh day, separately or jointly, on activity of GPx in the whole
brain, cortex and hippocampus of mice. Data are presented as the means±
SEM; n=8–12; ***p<0.001 versus saline-treated control group,
#p<0.05, ##p<0.01 versus scopolamine-treated control group; Tukey’s
test
Treatment GPx [U/g protein]
Brain Cortex Hippocampus
Saline 15.87±0.55 64.29±1.88 62.48±2.88
SCP 10.07±1.01*** 48.01±2.49*** 32.91±2.27***
IMP 1 mg/kg 12.99±0.45 65.66±2.65 62.14±2.19
IMP 1 mg/kg+SCP 11.26±0.99 53.93±2.62 32.40±3.21
IMP 5 mg/kg 14.91±0.93 67.29±4.42 55.03±4.00
IMP 5 mg/kg+SCP 12.38±0.87 67.94±1.50## 41.56±2.24
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p<0.0001], treatment [F(3,88)=3.86, p=0.0121] without in-
teractions effect [F(3,88)=2.09, p<0.1078]) and the hippo-
campus (pretreatment [F(1,88)=47.86, p<0.0001] without
treatment effect [F(3,88)=0.21, p=0.8926] and interaction
effect [F(3,88)=0.73, p=0.5373]) as presented in Table 5.
The post hoc Tukey’s test showed that scopolamine injection
caused a significant decrease in GR activity in the cortex
(p<0.001) and hippocampus (p<0.001) as compared with
saline-treated control group. Additionally, the highest dose
of imperatorin (10 mg/kg) administered subchronically before
scopolamine (1 mg/kg) injection was found to cause a signif-
icant increase in GR activity in the prefrontal cortex (p<0.05)
as compared with scopolamine-treated control group.
The effect of scopolamine and imperatorin, as well as their
combined administration in the concentration of MDA, the
main product of lipids peroxidation, is presented in Table 6.
Two-way ANOVA indicated changes in MDA level in the
cortex (pretreatment [F(1,88)=251.16, p<0.0001] and inter-
actions [F(3,88)=21.91, p<0.0001] without treatment effect
[F(3,88)=1.40, p=0.2474]) and the hippocampus (pretreat-
ment [F(1,88)=54.77, p<0.0001] without treatment effect
[F(3,88)=0.14, p=0.9360] and interaction effect [F(3,88)=
2.36, p=0.0772]) of the experimental animals. The post hoc
Tukey’s test showed that scopolamine significantly increased
MDA concentration in the cortex and hippocampus as com-
pared with saline-treated mice (p<0.001). Moreover, all doses
of imperatorin (1, 5, and 10 mg/kg) administered repeatedly
before scopolamine injection caused decrease in MDA level
in the cortex (p<0.001) versus scopolamine-treated group.
The values of MDA concentration in the cortex after com-
bined administration of scopolamine and imperatorin were
statistically increased (1 and 5 mg/kg; p<0.001, 10 mg/kg;
p<0.05) as compared with imperatorin-treated groups. Also,
the post hoc Tukey’s showed that imperatorin significantly
increased MDA concentration in the cortex as compared with
saline-treated mice (5 mg/kg; p<0.05, 10 mg/kg; p<0.01).
Additionally, subchronic administration of imperatorin at the
doses of 5 and 10 mg/kg before scopolamine (1 mg/kg) injec-
tion was found to cause a significant decrease inMDA activity
in the hippocampus (p<0.05) as compared with scopolamine-
treated control group.
Discussion
In the present studies, imperatorin was examined for the first
time in order to prove whether this compound could amelio-
rate memory dysfunction induced by scopolamine. Our results
indicate that acute imperatorin injections at the doses of 5 and
10mg/kg improved the memory acquisition and consolidation
impaired by scopolamine (1 mg/kg). Moreover, only repeat-
able administration of the highest dose of imperatorin
(10 mg/kg) significantly attenuated the effects of scopolamine
on memory acquisition, whereas the doses of 5 and 10 mg/kg
of furanocoumarin were effective when memory consolida-
tion was measured. Furthermore, our results demonstrate the
enhancement of locomotor activity after scopolamine injec-
tions. Scopolamine has been generally found to increase lo-
comotor activity, already at the systemic doses of 0.056 mg/kg
and higher (Chintoh et al. 2003; Gholamreza et al. 2002;
Nomura et al. 1994). Thus, imperatorin at any used doses
did not modify the locomotor activity of mice or
scopolamine-induced effects. Our previous study has already
shown that acute and repeated administration of imperatorin
(10 and 20 mg/kg) improved different stages of memory
processes (both acquisition and consolidation) in the modified
Table 5 Effect of repeated administration of imperatorin (IMP; 1, 5, or
10 mg/kg, i.p.) and single scopolamine injection (SCP; 1 mg/kg, i.p.) on
the seventh day, separately or jointly, on activity of GR in the cortex and
hippocampus of mice. Data are presented as the means±SEM; n=8–12,
***p<0.001 versus saline-treated control group; #p<0.05 versus
scopolamine-treated control group; Tukey’s test




IMP 1 mg/kg 46.87±1.22 90.01±4.63
IMP 1 mg/kg+SCP 35.38±1.48 77.80±2.05
IMP 5 mg/kg 51.46±2.46 95.13±3.91
IMP 5 mg/kg+SCP 41.48±1.62 76.89±4.59
IMP 10 mg/kg 52.61±2.39 93.40±2.83
IMP 10 mg/kg+SCP 46.93±1.91# 82.16±4.06
Table 6 Effect of subchronic administration of imperatorin (IMP; 1, 5, or
10 mg/kg, i.p.) and single scopolamine injection (SCP; 1 mg/kg, i.p.) on
the seventh day, separately or in combination, on concentration of MDA
in the cortex and hippocampus of mice. Data are presented as the means±
SEM; n=8–12; *p<0.05, **p<0.01, ***p<0.001 versus saline-treated
control group, #p<0.05, ###p<0.001 versus scopolamine-treated control
group, &p<0.05, &&&p<0.001 versus imperatorin-treated control
group; Tukey’s test




IMP 1 mg/kg 12.34±0.41 3.817±0.25
IMP 1 mg/kg+SCP 19.59±0.86###, &&& 5.582±0.28
IMP 5 mg/kg 13.76±0.51* 3.986±0.33
IMP 5 mg/kg+SCP 18.63±0.87###, &&& 5.699±0.42#
IMP 10 mg/kg 14.30±0.64** 4.196±0.35
IMP 10 mg/kg+SCP 17.64±0.57###, & 5.121±0.29#
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EPM test, a different animal task used to measure cognitive
effects in rodents (Budzynska et al. 2012). Our experiments
also demonstrated that both acute and repeatable injections of
the subthreshold dose of imperatorin (1 mg/kg) improved
memory and learning processes when coadministered with
the inactive dose of nicotine in the PA paradigm (Budzynska
et al. 2013).
Imperatorin was shown to inhibit the activity of AChE,
which is an enzyme responsible for degradation of acetylcho-
line (ACh), the neurotransmitter essential for cognitive func-
tion (Loizzo et al. 2008). Also, it is well established that the
cholinergic neurotransmission system in the basal forebrain
plays an important role in learning and memory, and thus
maintaining ACh level is critical for the brain function (Blake
et al. 2014). Moreover, memory deficits associated with AD
may be due to the damage of the cholinergic pathways in the
brain (Buckingham et al. 2009; Snowden et al. 2011). Thus,
current therapeutic approach for treating AD is the AChE
inhibitors that increase the availability of ACh in the central
cholinergic synapses, such as donepezil, rivastigmine, and
galantamine (Terry and Buccafusco 2003), as well as acting
on the glutamatergic system by blocking NMDA-type gluta-
mate receptors (memantine) (Rountree et al. 2009). However,
new drugs are needed to treat patients with AD, because
current drugs may exert side effects such as gastrointestinal
disturbance or bradycardia (Rountree et al. 2009). Thus, in the
context of the present research, it is also important to mention
that adverse effects, like neurotoxicity, after the administration
of imperatorin have been reported after higher doses (329 and
443 mg/kg) than used in the present experiments (Łuszczki
et al. 2009). Moreover, chronic toxicological studies revealed
that imperatorin administered orally (p.o.) once daily for four
consecutive days at doses up to 150mg/kg did not affect blood
clotting and have little or no systemic (renal, hepatic, or
pulmonary) toxicity in mice (Kleiner et al. 2002).
Scopolamine is an anticholinergic drug that antagonizes the
muscarinic cholinergic receptors (mAChRs) (subtypes; M1
and M2). This agent is capable of producing deficits in the
processes of learning acquisition and consolidation
(Schmeller et al. 1995). Experimental data show that ACh
levels are significantly reduced in scopolamine-treated mice
(Giridharan et al. 2011). Scopolamine-induced amnesia is
connected with increased oxidative stress in the whole brain,
as well as in particular structures associated with memory and
learning (Pachauri et al. 2012). This compound was also
found to disturb metabolism especially for low molecular
weight antioxidants like glutathione, and therefore intensify
the level of lipids peroxidation within the brain (El-Sherbiny
et al. 2003), which is particularly vulnerable to reactive oxy-
gen species (ROS) action due to high abundance of highly
oxidable polyunsaturated fatty acids, such as arachidonic acid
and docosahexaenoic acid (Smith et al. 2007). Thus,
scopolamine-induced amnesia is a very well established
animal model of memory dysfunction, widely used to test
potential drugs of anti-Alzheimer's properties (Kanwal et al.
2010).
Therefore, in the present studies, we used this animal
model of AD, in which we provoked scopolamine-induced
memory deficits, to investigate the pro-cognitive properties of
imperatorin in the PA test. This test is a fear-motivated para-
digm, useful for evaluating the effects of novel chemical
molecules on learning and memory as well as studying the
mechanisms involved in cognition, in small laboratory animal
(Tsuji et al. 2003). In this model, the cognitive impairment
was induced by scopolamine and imperatorin pretreatment
was able to prevent the cognitive decline as the scopolamine-
induced shortening of the step-through latencywas successfully
restored by imperatorin administered acutely and repeatable.
In the context of the present study, we can expect that the
mechanism responsible for the cognitive improvement in-
duced by imperatorin may depend on the inhibition of AChE
activity. Many reports indicate that inhibited AChE activity
leads to an increased ACh levels in the brain, especially in the
central cortex and hippocampus, the two major areas involved
in the cognitive processes (Fayuk and Yakel 2004). Thus, high
ACh concentrations improved cognition in humans and in
several memory and learning models in rodents (Canal and
Imbimbo 1996; Knoppman 2001). Our study also showed that
acute injection of AChEI, rivastigmine, improves acquisition
and consolidation of cognitive processes in PA test, thereby
affirming the important role of ACH in cognitive functions.
As compared with imperatorin, this effect was more marked
what may suggest the different degrees of inhibition of the
enzyme by this compounds. However, our data may further
suggest that the ameliorating effects of imperatorin on mem-
ory deficit might have resulted from the modulation of ACh
levels through an inhibition of AChE enzyme.
Additionally, imperatorin administered subchronically has
a different impact on scopolamine-induced memory impair-
ment depending on phases of memory processes. This cou-
marin administered at the dose of 5 mg/kg attenuated
scopolamine-induced memory consolidation impairment
whereas did not improve impaired memory acquisition. These
positive effects of imperatorin on the scopolamine-induced
memory impairment during consolidation trial can be con-
nected with the involvement of the different type of choliner-
gic receptors in the partial stages of memory. In behavioral
studies on animals, it has been found that agonists of cholin-
ergic muscarinic receptor, injected after earlier training, im-
prove cognitive processes. Thus, it seems that stimulation of
cholinergic receptors, especially muscarinic, is an important
process for memory consolidation step not followed by acqui-
sition phase (Power et al. 2003). Moreover, the data indicated
that modulation of memory consolidation processes through
administration of drugs after having a workout depends on
small amygdala. The injection of muscarinic receptor agonist
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to amygdala after preceded by training improved the memory
processes (McGaugh et al. 1993).
Another beneficial property of imperatorin found in the
present study is the potential antioxidant activity. It is gener-
ally accepted that oxidative stress is significant in the forma-
tion of the pathology of AD. Experimental data suggest that
during latent period of the disease the accumulation of oxida-
tive damage processes can appear. This action leads to sudden
appearance of clinical symptoms of AD, including cognitive
deficits (Bonda et al. 2010). Several reports highlight the
potential role of anti-oxidant therapeutic agents in the treat-
ment of AD (Gilgun-Sherki et al. 2003).
It is well established that reactive oxygen species (ROS) are
generated during normal metabolism. However, oxidative
stress, which is an imbalance between ROS production and
antioxidant capacity of an organism, is associated with nu-
merous diseases (as cancer, cardiovascular disease, atheroscle-
rosis, hypertension, etc.) also including neurodegenerative
diseases (AD and Parkinson's disease) (Valko et al. 2007).
Increased generation of free radicals can result from side
effects of applied medical treatment, course of some diseases,
and normal ageing of an organism.
Our paper confirms that scopolamine significantly in-
creased MDA concentration, but we also revealed a strong
impact of scopolamine administration on antioxidant enzymes
activity, which was not stated previously (El-Sherbiny et al.
2003). The authors postulated scopolamine influence on glu-
tathione level; however, they did not notice changes in GPx
and SOD activity. Although we did not examined GSH level,
our findings confirm scopolamine influences on that antioxi-
dant through enzymes responsible for GSH turnover, i.e., GPx
and GR, whose activities were significantly increased after
scopolamine injection. Our study also revealed that scopol-
amine application did not cause significant changes in SOD
activity in the whole brain, what was in accordance with the
findings of El-Sherbiny et al. (2003). However, when partic-
ular brain structures connected with memory acquisition and
consolidation were examined, a significant increase in SOD
activity was stated in a group of mice which received a single
amnesic dose of scopolamine in comparison with the saline-
treated control group.
Coumarins, as well as their derivatives, were found to exert
strong antioxidant and anti-inflammatory effects (Kostova
2006; Vianna et al. 2012). These compounds were stated to
affect formation and scavenging of ROS and influence pro-
cesses involving free radical-mediated injury in a similar way
to flavonoids (Fylaktakidou et al. 2004). Many coumarins are
recognized as lipoxygenase and cyclooxygenase inhibitors
(Kontogiorgis et al. 2006), which are able to arrest or slow
down pathological processes caused by increased activities of
these enzymes, including production of neuroinflammation
involving vasodilation and vasoconstriction, platelet
aggregation, leukocyte chemotaxis and release of cytokines,
and oxidative stress. Antioxidant properties of imperatorin
were postulated by Cao et al. (2013) in the 2-kidney, 1-clip
(2 K, 1C) model of hypertension used to investigate the
potential antihypertensive effect. Other reports revealed that
imperatorin inhibited superoxide dismutase (Raja et al. 2011),
as well as decrease myeloperoxidase activity (Sun et al. 2012).
Moreover, our previous studies also confirmed antioxidative
properties of this coumarin. Imperatorin restrained nicotine-
induced oxidative stress in examined brain structures, i.e., the
hippocampus and cortex (Budzynska et al. 2013).
Our study revealed that treatment with imperatorin was
found to reverse scopolamine-induced memory impairment
in mice probably by reducing oxidative stress within the CNS.
Our outcomes implied that subchronic administration of im-
peratorin was able to overwhelm pro-oxidant effects of sco-
polamine in the brain, i.e., an increase in antioxidant enzymes
(SOD, GPx, and GR) activities and a decrease in MDA
concentration. Interestingly, the changes were well-marked
in single brain structures, the prefrontal cortex and hippocam-
pus, rather than in the whole brain indicating specific scopol-
amine action in brain regions implicated in learning and
memory processes.
However, according to our results, the antioxidant effect of
imperatorin is dose-dependent and strongly correlated with
memory and learning processes. The lowest dose (1 mg/kg)
was found inactive, i.e., did not affected antioxidant barrier
parameters as well as did not improved memory processes,
while the higher doses (5 and 10mg/kg) induced a statistically
significant increase antioxidant enzymes activity and decrease
MDA level as well as caused memory improvement in behav-
ioral tests. The dose of imperatorin, 1 mg/kg, was also inef-
fective in the PA test. Coumarin administered acutely and
subchronically at this dose did not influence cognitive pro-
cesses, as well as did not improve memory and learning
processes impaired by administration of scopolamine.
The current results do not provide a clear mechanism by
which imperatorin affects memory processes. However, ob-
tain results may suggest that imperatorin may be able to
ameliorate memory impairments caused by cholinergic dys-
function through inhibition of AChE activity as well as inhi-
bition of oxidative stress-related processes. The present stud-
ies demonstrated that acute and subchronic administration of
imperatorin improved the scopolamine-induced memory ac-
quisition and consolidation impairment in PA test in mice.
Furthermore, we may conclude that observed antiamnestic
effects of imperatorin may be attributed to antioxidant, and
therefore neuroprotective properties of that furocoumarin.
Currently, there is no cure for AD and additional preclinical
studies may contribute to the development of more effective
and devoided of significant side effects AD pharmacotherapy.
Based on the present results, we can speculate that imperatorin
may become a new treatment strategy which will change the
course of the disease and improve the quality of life of people
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with dementia. Additionally, antioxidant prophylactics may
be beneficial for people with a genetic risk factor for AD
occurrence.
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